Table 3. Transplant outcomes for all patients.
All patients | By donor type | ||||
---|---|---|---|---|---|
Measure | N=227 | MRD (N=87) | MUD (N=108) | Haplo (N=32) | |
| |||||
Day 30 chimerism | |||||
| |||||
Donor engraftment | |||||
| |||||
n | 216, | 87 | 98 | 31, | |
| |||||
n (%) | 210 (97) | 86 (99) | 94 (96) | 30 (97) | 0.441a |
| |||||
100% donor | |||||
| |||||
n | 208, | 85, | 93, | 30, | |
| |||||
n (%) | 204 (98) | 84 (99) | 90 (97) | 30 (100) | 0.798a |
| |||||
CMV reactivation | |||||
| |||||
n | 224 | 87 | 106 | 31 | |
| |||||
n (%) | 121 (54) | 42 (48) | 57 (54) | 22 (71) | 0.098a |
| |||||
EBV reactivation | 0 | 0 | 0 | 0 | - |
| |||||
CI aGVHD 2-4 (%) Day 100 | 30 | 31 | 29 | 29 | 0.709b |
| |||||
CI aGVHD 3-4 (%) Day 100 | 7 | 11 | 6 | 0 | 0.044b |
| |||||
CI cGVHD (Ext+Lim) (%) Year 3 | 34 | 43 | 30 | 19 | 0.094b |
| |||||
CI cGVHD (Ext) (%) Year 3 | 24 | 31 | 21 | 11 | 0.125b |
| |||||
Follow-up survivors Median (range), mo | 31 (0.8–85.4) | 45 (6.4-78.8) | 40 (0.8-85.4) | 13 (1.6-31.2) | <0.001c |
| |||||
CI Relapse (%) | 0.750b | ||||
Day 100 | 8 | 7 | 8 | 10 | |
4 | 0 | 0 | |||
Year 1 | 26 | 28 | 23 | 33 | |
| |||||
CI Non-relapse mortality (%) | 0.099b | ||||
Day 100 | 18 | 10 | 26 | 13 | |
Year 1 | 27 | 20 | 35 | 24 | |
| |||||
Progression free survival (%) | 0.120d | ||||
Day 100 | 74 | 83 | 65 | 78 | |
Year 1 | 46 | 52 | 42 | 43 | |
Year 3 | 31 | 36 | 27 | 30 | |
Median (95% confidence interval) days | 284 (215, 404) | 411 (237, 757) | 238 (160, 386) | 276 (173, NE) | |
| |||||
10/10 | 10/10 | 5/10 |
a: acute; c: chronic; CI: cumulative incidence; CMV: cytomegalovirus; EBV: Epstein-Barr virus; CR: complete remission; ext: extensive; haplo: haploidentical donor; lim.: limited; Mel: melphalan; mo: month; MRD: matched related donor; MUD: matched unrelated donor;, n: number; NE = not estimable;
: Fisher's exact test.
: Gray's test.
: Kruskal-Wallis test.
: Log-rank test.